Insmed Announces Fourth Quarter and Full-Year 2007 Financi...( RICHMOND Va. March 4 /- Insmed In...)

RICHMOND, Va., March 4 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq CM: INSM), a developer of follow-on biologics and biopharmaceuticals, today reported results for the quarter and full-year ended December 31, 2007.

Full-Year 2007 and Recent Company Highlights

-- Follow-on Biologics Program

-- Completed development of INS-19 (Granulocyte Colony Stimulating

Factor or G-CSF) and INS-20 (Peg G-CSF), positioning these

products to enter clinical trials in 2008;

-- Testified at two congressional hearings - "Safe and Affordable

Biotech Drugs - The Need for a Generic Pathway" and "Assessing the

Impact of a Safe and Equitable Biosimilar Policy in the United

States" where Geoffrey Allan, Ph.D., the Company's President and

CEO, urged the need to create a regulatory pathway for the

approval of follow-on biologics ("FOBs") in the U.S.;

-- Appointed Steve Glover, who has approximately 25 years of

biotechnology experience, as President of the Company's FOB

program in order to most effectively leverage Insmed's scientific

capabilities in the field;

-- Completed external market assessment using a major U.S. market

research firm, which indicated a $9 billion annual market

potential for the Company's FOB candidates whose corresponding

innovator products' patents expire within the next eight years;

-- Launched a broad education campaign on the importance of

establishing a regulatory pathway for FOBs in the U.S.; and

-- Commissioned econometric study by economist Dr. Robert J. Shapiro,

former Under Secretary of Commerce in the Clinton Administration,

that identified potential cost savings of approximately $378

billion over the next 20 years from making FOBs a
'/>"/>